Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-OVV-mIL33
- Development stage
- Preclinical
- Lead developer
- Genvira Biosciences
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
**MSC-OVV-mIL33** is a preclinical mesenchymal stem cell-mediated delivery product containing an oncolytic vaccinia virus engineered to express murine interleukin-33. The mesenchymal stem cell carrier is intended to shield the virus from neutralization and improve tumor delivery, while intratumoral viral replication promotes tumor-cell lysis and local IL-33 expression remodels the tumor immune microenvironment. In murine PD-1 inhibitor-resistant bladder cancer models, MSC-OVV-mIL33 combined with PD-1 blockade increased cytotoxic CD8-positive T-cell, memory B-cell, and type 2 innate lymphoid cell infiltration while reducing regulatory T cells and terminally exhausted CD8-positive T cells. The program was reported by Guangxi Medical University Cancer Hospital and Genvira Biosciences in an AACR 2026 abstract.
- Other names
- MSC-OVV-mIL33MSC-OVV-mIL-33MSC-OVV-mIL 33
02
Targets
IL1RL1 (Interleukin 1 receptor-like 1 protein)
Beyond the preview
Go deeper on MSC-OVV-mIL33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-OVV-mIL33.